B7-H3B7-H3-targeted ADCsimmunotherapyclinicaltrials.govbrain metastasesmetastatic triple-negative breast cancer (TNBC)metastatic TNBCTNBC
…which yielded eight phase I/II trials examining the efficacy of B7-H3 ADCs, 12.5% (n=1/8) of which exclude patients with brain metast…